Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing-Reference-Cited by-同舟云学术

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing

Published:2017-08-24 Issue:8 Volume:12 Page:e0183390
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ross Sandra L.,Sherman Marika,McElroy Patricia L.,Lofgren Julie A.,Moody Gordon,Baeuerle Patrick A.,Coxon Angela,Arvedson Tara^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference55 articles.

1. Bispecific T-cell engaging antibodies for cancer therapy;P Baeuerle;Cancer Research,2009

2. Bispecific T-cell engagers for cancer immunotherapy;A Huehls;Immunology and cell biology,2015

3. Harnessing T cells to fight cancer with BiTE antibody constructs—past developments and future directions;M Klinger;Immunological reviews,2016

4. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study;M-E Goebeler;Journal of Clinical Oncology,2016

5. Targeting T cells to tumor cells using bispecific antibodies;S Frankel;Current opinion in chemical biology,2013

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mosunetuzumab for the treatment of follicular lymphoma;Expert Opinion on Biological Therapy;2024-09-11

2. Current landscape of CD3 bispecific antibodies in hematologic malignancies;Trends in Cancer;2024-08

3. Contemporary Approaches to Immunotherapy of Solid Tumors;Cancers;2024-06-19

4. Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future;Frontiers in Pharmacology;2024-05-30

5. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer;Cancer Biology & Therapy;2024-05-27